Alzheimer's IV drug plans cancelled
Tuesday, August 7, 2012 - 10:00
in Health & Medicine
Pharmaceutical companies say they are ending development of an intravenous formulation of the drug bapineuzumab to treat Alzheimer's disease after it failed in two late-stage clinical trials.